Implantable Port-a-Cath System Insertion in Patients with Metastatic Colon Cancer Receiving Bevacizumab-Based Chemotherapy View PDF

^*Tal Grenader
Department Of Oncology, Shaare Zedek Medical Center, Jerusalem , Israel

^*Corresponding Author:

Tal Grenader
Department Of Oncology, Shaare Zedek Medical Center, Jerusalem , Israel
Email:talgrenader65@hotmail.com

Published on: 2015-02-17

Abstract

Combination of bevacizumab with continuous 5- fluoracil (5-FU)-based regimens are considered to be the backbone of colorectal cancer (CRC) systemic therapy. Administration of these continuous intravenous regimens requires insertion of an indwelling central venous catheters and implantable port systems. Certain aspects of the toxicity profile of Bevacizumab could interfere with implantable port-a-cath insertion. The aim of present study was to evaluate the safety port-a-cath insertion shortly before or during bevacizumab treatment in patients with metastatic colon cancer.

Keywords

Metastatic colon cancer; Port-a-cath; Implantable venous access catheter; Bevacizumab; Wound healing

Introduction

Colorectal cancer (CRC) is one of the most common types of cancer worldwide. Approximately 25% present with metastases at initial diagnosis and almost 50% of patients with CRC will develop metastases.